Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
None
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib

bortezomib
dexamethasone
measurable disease
chemotherapy regimen
lenalidomide
  • 0 views
  • 19 Nov, 2021
  • 4 locations
None
  • 0 views
  • 03 May, 2021
  • 1 location
None
Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma

, and magrolimab + bortezomib + dexamethasone. The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer

platelet count
refractory multiple myeloma
granulocyte colony stimulating factor
bortezomib
neutrophil count
  • 0 views
  • 27 Nov, 2021
  • 1 location
None
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Burkitt Lymphoma/Leukemia or Double-Hit Lymphoma/Leukemia

, dexamethasone and bortezomib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

burkitt's lymphoma
glomerular filtration rate
tumor cells
cyclophosphamide
tyrosine
  • 27 views
  • 24 Jan, 2021
  • 2 locations
None
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

safely and effectively discontinue post-transplant maintenance therapy (single agent lenalidomide, pomalidomide, bortezomib, or ixazomib) after receiving at least one year of maintenance therapy.

bortezomib
pomalidomide
ixazomib
maintenance therapy
revlimid
  • 22 views
  • 28 Jan, 2021
  • 1 location
None
Study of Daratumumab Combined With Carfilzomib Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

. Daratumumab has shown to be effective in subjects with MM when combined with medicines like bortezomib, or lenalidomide + dexamethasone.

vasectomy
ejection fraction
neutrophil count
daratumumab
cancer
  • 0 views
  • 17 Oct, 2021
  • 1 location
None
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Induction chemotherapy 1) RCHOP(Rituximab+Cyclophosphamide+Doxorubicin+Vincristine+Prednisone) 2) VR-CAP (Bortezomib+Rituximab+Cyclophosphamide+Doxorubicin+Prednisone)

ejection fraction
bortezomib
mantle cell lymphoma
neutrophil count
cyclin d1
  • 2 views
  • 25 Jan, 2021
  • 1 location
None
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

,thrombopoietin-receptor agonists(TPO-RA) ,bortezomib or splenectomy,have been largely unsatisfactory. As we know, HLA antibodies are mainly secreted by the plasma cells. Researchers want to see if sequential

  • 0 views
  • 06 Nov, 2021
  • 1 location
None
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

dexamethasone (DPd); 2) Pomalidomide (POM) in combination with bortezomib (BTZ) and low-dose dexamethasone (PVd) Combination agents being tested may be administered before, concurrently with and/or

corticosteroids
dexamethasone
measurable disease
bortezomib
  • 0 views
  • 22 Sep, 2021
  • 24 locations
None
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

This is a multicenter, open label clinical trial evaluating the safety of the combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone) in

melphalan
lenalidomide
filgrastim
bortezomib
colony stimulating factor
  • 0 views
  • 08 Dec, 2021
  • 18 locations